


CLAIMS

1. A peptidomimetic compound of the general formula (I),



5 (I)

wherein

P¹ is 2OHVal, Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cha, Cpa, Cpg, Cyg, Dea, Gly, Hle, Ile, Leu, Met, Nle, OctGly, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva;

10 wherein the amino group of P¹ is optionally replaced by a guanidino group (Gua) or by a tetramethyl guanidino (TMG) group;

P² is Pro, Pro(4R)F, Pro(4R)OMe, Pro(4R)OPhe, Pro(3,4dehydro), Pr(4,4F2), Pic; Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys; Hyp, NalloThr;

P³ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cha, Cpa, Cpg, Cyg, Dea, Gly, Hle, Ile, Leu, Met, Nle, OctGly, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva;

P⁴ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cha, Cpa, Cpg, Cyg, Dea, Gly, Hle, Ile, Leu, Met, Nle, OctGly, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva;

20 Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe; Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys, Lys(Me); alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl, Val(3OH);

25 P⁵ is Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;

30

- P⁶ is Pra, Abu(4N₃);
 Dab, Dap, ^DDab, ^DDap;
 Cys, Hcy, NMeCys, Pen, ^DCys, ^DHcy, ^DNMeCys, ^DPen;
 Asp, Glu, Hgl, ^DAsp, ^DGlu, ^DHgl;
- 5 P⁷ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cha, Cpa, Cpg, Cyg,
 Dea, Gly, Hle, Ile, Leu, Met, Nle, OctGly, Sar, tBuGly, tBuAla, Val, Pro, NMeAla,
 NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 10 2OHDab, Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab,
 Nlys, Norn, Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg,
 NMeLys;
 alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P⁸ is Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 15 Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys;
- P⁹ is Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys;
 Cit;
- P¹⁰ is alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- 20 P¹¹ is ^DDab, ^DDab(iPr), ^DDap, ^DDap(iPr), ^DLys, ^DLys(iPr), ^DOrn, ^DOrn(iPr), ^DArg;
- P¹² is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cha, Cpa, Cpg, Cyg,
 Dea, Gly, Hle, Ile, Leu, Met, Nle, OctGly, Sar, tBuGly, tBuAla, Val, Pro, NMeAla,
 NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 25 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys;
 alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹³ is Pra, Abu(4N₃);
 30 Dab, Dap, ^DDab, ^DDap;

Cys, Hcy, NMeCys, Pen, ^DCys, ^DHcy, ^DNMeCys, ^DPen;

Asp, Glu, Hgl, ^DAsp, ^DGlu, ^DHgl;

P¹⁴ is Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;

5 Agb, Agp, Dab, Dab(iPr); Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys;
alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;

P¹⁵ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cha, Cpa, Cpg, Cyg,
Dea, Gly, Hle, Ile, Leu, Met, Nle, OctGly, Sar, tBuGly, tBuAla, Val, Pro, NMeAla,
10 NMeVal, Nva;

Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys;
alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;

P¹⁶ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cha, Cpa, Cpg, Cyg,
15 Dea, Gly, Hle, Ile, Leu, Met, Nle, OctGly, Sar, tBuGly, tBuAla, Val, Pro, NMeAla,
NMeVal, Nva;

Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;

or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof,

20 wherein

Cys, Hcy, NMeCys or Pen at P⁶, if present, and Cys, Hcy, NMeCys or Pen at P¹³, if
present, optionally form a disulfide bridge between P⁶ and P¹³; or wherein

^DCys, ^DHcy, ^DNMeCys or ^DPen at P⁶, if present, and ^DCys, ^DHcy, ^DNMeCys or ^DPen at P¹³,
if present, optionally form a disulfide bridge between P⁶ and P¹³; or wherein

25 Dab or Dap at P⁶, if present, and Asp, Glu or Hgl at P¹³, if present, optionally form a
lactam bridge between P⁶ and P¹³; or wherein

^DDab or ^DDap at P⁶, if present, and ^DAsp, ^DGlu or ^DHgl at P¹³, if present, optionally form
a lactam bridge between P⁶ and P¹³; or wherein

Asp, Glu or Hgl at P⁶, if present, and Dab or Dap at P¹³, if present, optionally form a

30 lactam bridge between P⁶ and P¹³; or wherein

^DAsp, ^DGlu or ^DHgl at P⁶, if present, and ^DDab or ^DDap at P¹³, if present, optionally form a lactam bridge between P⁶ and P¹³; or wherein

Pra at P⁶, if present, and Abu(4N₃) at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³; or wherein

5 Abu(4N₃) at P⁶, if present, and Pra at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³;

with the proviso that at least three amino acid residues among the four amino acid residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn,

10 Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys.

2. The compound of claim 1, wherein

P¹ is 2OHVal, Val, NMeVal, Abu, tBuGly;

wherein the amino group of P¹ is optionally replaced by a guanidino group (Gua)

15 or by a tetramethyl guanidino (TMG) group;

P² is Pro, Pro(4R)F, Pro(4R)OMe, Pro(4R)OPhe, Pro(3,4dehydro), Pr(4,4F2), Pic;

Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys; Hyp, *Nallo*Thr;

20 P³ is Hle, Ile, Leu, Nle;

P⁴ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolile, Cha, Cpa, Cpg, Cyg, Dea, Hle, Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;

Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;

25 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys, Lys(Me);

alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl, Val(3OH);

P⁵ is Phe, His, Trp, Tyr;

P⁶ is Pra, Abu(4N₃);

30 Dab, Dap;

- Cys, Hcy, NMeCys, Pen;
 Asp, Glu, Hgl;
- 5 P⁷ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cha, Cpa, Cpg, Cyg, Dea, Hle,
 Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Phe(4OCF3), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH2), Tyr(Me), Ntyr, Nphe;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Arg, NMeLys; Group E
 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- 10 P⁸ is Agb, Har, Arg;
 P⁹ is Dab, Dap, Har, Lys, Orn, Arg, Dab(iPr);
 Cit;
 P¹⁰ is alloThr, Hse, Ser, Thr;
 P¹¹ is ^DDab, ^DDap, ^DLys, ^DOrn, ^DArg, ^DDab(iPr);
- 15 P¹² is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cha, Cpa, Cpg, Cyg, Dea, Hle,
 Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Phe(4OCF3), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH2), Tyr(Me), Ntyr, Nphe;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 20 Orn, Orn(iPr), Arg, NMeLys;
 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹³ is Pra, Abu(4N₃);
 Dab, Dap;
 Cys, Hcy, NMeCys, Pen;
- 25 Asp, Glu, Hgl;
- P¹⁴ is Phe, His, Phe(3OH), Phe(4F), Phe(4OCF3), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH2), Tyr(Me), Ntyr, Nphe;
 Agb, Agp, Dab, Dab(iPr); Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Arg, NMeLys;
- 30 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;

- P¹⁵ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, alloIle, Cha, Cpa, Cpg, Cyg, Dea, Hle, Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva; Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys;
- 5 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹⁶ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, alloIle, Cha, Cpa, Cpg, Cyg, Dea, Hle, Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva; Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
- 10 or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof, wherein
- Cys, Hcy, NMeCys or Pen at P⁶, if present, and Cys, Hcy, NMeCys or Pen at P¹³, if present, optionally form a disulfide bridge between P⁶ and P¹³; or wherein
- Dab or Dap at P⁶, if present, and Asp, Glu or Hgl at P¹³, if present, optionally form a
- 15 lactam bridge between P⁶ and P¹³; or wherein
- Asp, Glu or Hgl at P⁶, if present, and Dab or Dap at P¹³, if present, optionally form a lactam bridge between P⁶ and P¹³; or wherein
- Pra at P⁶, if present, and Abu(4N₃) at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³; or wherein
- 20 Abu(4N₃) at P⁶, if present, and Pra at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³;
- with the proviso that at least three amino acid residues among the four amino acid residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn,
- 25 Orn(iPr), Arg, NMeLys.

3. The compound according to any one of claims 1 or 2, wherein

- P¹ is 2OHVal, Val, NMeVal, Abu, tBuGly;
- wherein the amino group of P¹ is optionally replaced by a guanidino group (Gua)
- 30 or by a tetramethyl guanidino (TMG) group;

- P² is Pro, Pro(4R)F, Pro(4R)OMe, Pro(4R)OPhe, Pro(3,4dehydro), Pr(4,4F2), Pic;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Pro((4R)guanidine), Pro((4R)NH₂), Pro((4S)NH₂), Arg, NMeLys;
 Hyp, NalloThr;
- 5 P³ is Ile;
- P⁴ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cha, Cpa, Cpg, Cyg, Dea, Hle,
 Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 10 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Arg, NMeLys, Lys(Me);
 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl, Val(3OH);
- P⁵ is Phe, His, Trp, Tyr;
- P⁶ is Dab, Dap;
- 15 Cys, Pen;
 Asp, Glu;
- P⁷ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cha, Cpa, Cpg, Cyg, Dea, Hle,
 Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 20 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Arg, NMeLys;
 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P⁸ is Arg;
- 25 P⁹ is Dab, Dap, Har, Lys, Orn, Arg, Dab(iPr);
 Cit;
- P¹⁰ is alloThr, Hse, Ser, Thr;
- P¹¹ is ^DDab, ^DDap, ^DLys, ^DOrn, ^DArg, ^DDab(iPr);
- P¹² is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cha, Cpa, Cpg, Cyg, Dea, Hle,
 30 Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;

- Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Arg, NMeLys;
 5 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
 P¹³ is Dab, Dap;
 Cys, Pen;
 Asp, Glu;
 P¹⁴ is Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 10 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 Agb, Agp, Dab, Dab(iPr); Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Arg, NMeLys;
 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, or Hgl;
 P¹⁵ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cha, Cpa, Cpg, Cyg, Dea, Hle,
 15 Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn,
 Orn, Orn(iPr), Arg, NMeLys;
 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, or Hgl;
 P¹⁶ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cha, Cpa, Cpg, Cyg, Dea, Hle,
 20 Ile, Leu, Met, Nle, OctGly, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Phe(4OCF₃), Trp(6Cl), Tyr(3Cl), Tyr(3F), Tyr(Phenyl),
 Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof,
 wherein
 25 Cys or Pen at P⁶, if present, and Cys or Pen at P¹³, if present, optionally form a disulfide
 bridge between P⁶ and P¹³; or wherein
 Dab or Dap at P⁶, if present, and Asp or Glu at P¹³, if present, optionally form a lactam
 bridge between P⁶ and P¹³; or wherein
 Asp or Glu at P⁶, if present, and Dab or Dap at P¹³, if present, optionally form a lactam
 30 bridge between P⁶ and P¹³;

with the proviso that at least three amino acid residues among the four amino acid residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Har, Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys.

5

4. The compound of claim 1, wherein

P¹ is 2OHVal, Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cyg, Dea, Gly, Ile, Leu, Nle, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva;

wherein the amino group of P¹ is optionally replaced by a guanidino group (Gua)

10 or by a tetramethyl guanidino (TMG) group;

P² is Pro, Pro(4R)F, Pro(4R)OMe, Pro(4R)OPhe, Pro(3,4dehydro), Pr(4,4F2), Pic; Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)NH₂), Arg, NMeLys;

Hyp, NalloThr;

15 P³ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cyg, Dea, Gly, Ile, Leu, Nle, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva;

P⁴ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cyg, Dea, Gly, Ile, Leu, Nle, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva;

Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)),

20 Phe(4NH₂), Tyr(Me), Ntyr, Nphe;

Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)NH₂), Arg, NMeLys, Lys(Me);

alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl, Val(3OH);

25 P⁵ is Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;

P⁶ is Pra, Abu(4N₃);

Dab, Dap;

Cys, Hcy, NMeCys, Pen;

30 Asp, Glu, Hgl;

- P⁷ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cyg, Dea, Gly, Ile, Leu, Nle, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva;
Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
- 5 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)NH₂), Arg, NMeLys;
alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P⁸ is Agb, Agp, Dab, Dap, Lys, Narg, Ndab, Nlys, Norn, Orn, Pro((4R)NH₂), Arg, NMeLys;
- P⁹ is Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn,
10 Orn(iPr), Pro((4R)NH₂), Arg, NMeLys;
Cit;
- P¹⁰ is alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹¹ is ^DDab, ^DDab(iPr), ^DDap, ^DDap(iPr), ^DLys, ^DLys(iPr), ^DOrn, ^DOrn(iPr), ^DArg;
- P¹² is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, betaGly, Cyg, Dea, Gly, Ile,
15 Leu, Nle, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva;
Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Tyr(Phenyl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)NH₂), Arg, NMeLys;
- 20 alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹³ is Pra, Abu(4N₃);
Dab, Dap;
Cys, Hcy, NMeCys, Pen;
Asp, Glu, Hgl;
- 25 P¹⁴ is Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
Agb, Agp, Dab, Dab(iPr); Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)NH₂), Arg, NMeLys;
alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;

- P¹⁵ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolIle, betaGly, Cyg, Dea, Gly, Ile, Leu, Nle, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva; Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)NH₂), Arg, NMeLys;
- 5 alloThr, Cit, Hgn, Hse, Hyp, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹⁶ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolIle, betaGly, Cyg, Dea, Gly, Ile, Leu, Nle, Sar, tBuGly, tBuAla, Val, Pro, NMeAla, NMeVal, Nva; Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
- 10 or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof, wherein
- Cys, Hcy, NMeCys or Pen at P⁶, if present, and Cys, Hcy, NMeCys or Pen at P¹³, if present, optionally form a disulfide bridge between P⁶ and P¹³; or wherein
- Dab or Dap at P⁶, if present, and Asp, Glu or Hgl at P¹³, if present, optionally form a
- 15 lactam bridge between P⁶ and P¹³; or wherein
- Asp, Glu or Hgl at P⁶, if present, and Dab or Dap at P¹³, if present, optionally form a lactam bridge between P⁶ and P¹³; or wherein
- Pra at P⁶, if present, and Abu(4N₃) at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³; or wherein
- 20 Abu(4N₃) at P⁶, if present, and Pra at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³;
- with the proviso that at least three amino acid residues among the four amino acid residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from
- Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn,
- 25 Orn(iPr), Pro((4R)NH₂), Arg, NMeLys.

5. The compound according to any one of claims 1 or 4, wherein

- P¹ is 2OHVal, Val, NMeVal, Abu, tBuGly;
- wherein the amino group of P¹ is optionally replaced by a guanidino group (Gua)
- 30 or by a tetramethyl guanidino (TMG) group;

- P² is Pro, Pro(4R)F, Pro(4R)OMe, Pro(4R)OPhe, Pro(3,4dehydro), Pr(4,4F2), Pic;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn,
 Orn(iPr), Pro((4R)NH₂), Arg, NMeLys;
 Hyp, *Nallo*Thr;
- 5 P³ is *Hle*, Ile, Leu, Nle;
- P⁴ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly,
 tBuAla, Val, NMeAla, NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)),
 Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
- 10 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn,
 Orn(iPr), Arg, NMeLys, Lys(Me);
 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl, Val(3OH);
- P⁵ is Phe, His, Trp, Tyr;
- P⁶ is Pra, Abu(4N₃);
- 15 Dab, Dap;
 Cys, Hcy, NMeCys, Pen;
 Asp, Glu, Hgl;
- P⁷ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly,
 tBuAla, Val, NMeAla, NMeVal, Nva;
- 20 Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)),
 Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn,
 Orn(iPr), Arg, NMeLys;
 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- 25 P⁸ is Agb, Har, Arg;
- P⁹ is Dab, Dap, Har, Lys, Orn, Arg, Dab(iPr);
 Cit;
- P¹⁰ is alloThr, Hse, Ser, Thr;
- P¹¹ is ^DDab, ^DDap, ^DLys, ^DOrn, ^DArg, ^DDab(iPr);

- P¹² is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Tyr(Phenyl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
5 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys;
alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹³ is Pra, Abu(4N₃);
Dab, Dap;
10 Cys, Hcy, NMeCys, Pen;
Asp, Glu, Hgl;
- P¹⁴ is Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
Agb, Agp, Dab, Dab(iPr); Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys;
15 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹⁵ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys;
20 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹⁶ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
25 or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof,
wherein
Cys, Hcy, NMeCys or Pen at P⁶, if present, and Cys, Hcy, NMeCys or Pen at P¹³, if present, optionally form a disulfide bridge between P⁶ and P¹³; or wherein
30 Dab or Dap at P⁶, if present, and Asp, Glu or Hgl at P¹³, if present, optionally form a

lactam bridge between P⁶ and P¹³; or wherein

Asp, Glu or Hgl at P⁶, if present, and Dab or Dap at P¹³, if present, optionally form a lactam bridge between P⁶ and P¹³; or wherein

Pra at P⁶, if present, and Abu(4N₃) at P¹³, if present, optionally form a 1,2,3-triazole

5 bridge between P⁶ and P¹³; or wherein

Abu(4N₃) at P⁶, if present, and Pra at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³;

with the proviso that at least three amino acid residues among the four amino acid residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from

10 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys.

6. The compound according to any one of claims 1, 4 or 5, wherein

P¹ is 2OHVal, Val, NMeVal, Abu, tBuGly;

15 wherein the amino group of P¹ is optionally replaced by a guanidino group (Gua) or by a tetramethyl guanidino (TMG) group;

P² is Pro, Pro(4R)F, Pro(4R)OMe, Pro(4R)OPhe, Pro(3,4dehydro), Pr(4,4F2), Pic; Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Pro((4R)NH₂), Arg, NMeLys;

20 Hyp, *Nallo*Thr;

P³ is Ile;

P⁴ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;

Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)),

25 Phe(4NH₂), Tyr(Me), Ntyr, Nphe;

Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys; Lys(Me);

alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl, Val(3OH);

P⁵ is Phe, His, Trp, Tyr;

30 P⁶ is Dab, Dap;

- Cys, Pen;
Asp, Glu;
- 5 P⁷ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys;
alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- 10 P⁸ is Arg;
P⁹ is Dab, Dap, Har, Lys, Orn, Arg, Dab(iPr);
Cit;
P¹⁰ is alloThr, Hse, Ser, Thr;
P¹¹ is ^DDab, ^DDap, ^DLys, ^DOrn, ^DArg, ^DDab(iPr);
- 15 P¹² is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Tyr(Phenyl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys;
20 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
- P¹³ is Dab, Dap;
Cys, Pen;
Asp, Glu;
- 25 P¹⁴ is Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
Agb, Agp, Dab, Dab(iPr); Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys;
alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, or Hgl;

- P¹⁵ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys;
 5 alloThr, Cit, Hgn, Hse, Leu((3R)OH), Asn, Gln, Ser, Thr, Asp, Glu, Hgl;
 P¹⁶ is Ala, Ala(cPr), Ala(tetrahydropyran4yl), Abu, allolle, Cyg, Dea, Ile, Leu, Nle, tBuGly, tBuAla, Val, NMeAla, NMeVal, Nva;
 Phe, His, Phe(3OH), Phe(4F), Trp(6Cl), Trp, Tyr, 4Thz, Phe(4(4hydroxyphenoxy)), Phe(4NH₂), Tyr(Me), Ntyr, Nphe;
 10 or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof,
 wherein
 Cys or Pen at P⁶, if present, and Cys or Pen at P¹³, if present, optionally form a disulfide bridge between P⁶ and P¹³; or wherein
 Dab or Dap at P⁶, if present, and Asp or Glu at P¹³, if present, optionally form a lactam
 15 bridge between P⁶ and P¹³; or wherein
 Asp or Glu at P⁶, if present, and Dab or Dap at P¹³, if present, optionally form a lactam bridge between P⁶ and P¹³;
 with the proviso that at least three amino acid residues among the four amino acid residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from
 20 Agb, Agp, Dab, Dab(iPr), Dap, Dap(iPr), Lys, Lys(iPr), Narg, Ndab, Nlys, Norn, Orn, Orn(iPr), Arg, NMeLys.

7. The compound according to any one of claims 1 to 6, wherein

- P¹ is Val, 2OHVal, NMeVal, Gua-Val, TMG-Val, Abu, or tBuGly;
 25 P² is Pro, Pro(4R)F, Pro(4R)OMe, Pro(4R)OPhe, Pro(3,4dehydro), Pr(4,4F2), Pic, Pro((4R)NH₂), Ndab, NalloThr, or Hyp;
 P³ is Ile;
 P⁴ is Ile, Thr, Phe, Dab, Orn, Arg, Tyr, Leu, Asn, Lys, Lys(Me), Dap, Val(3OH), or alloThr;
 P⁵ is Trp or Tyr;
 30 P⁶ is Cys, Pen, Asp, or Pra;

- P⁷ is Asn, Ala, Leu, Ile, Ser, Thr, Lys, Dap, Glu, or His;
 P⁸ is Arg;
 P⁹ is Arg, Dab, Dab(iPr), Lys, or Cit;
 P¹⁰ is Ser or Thr;
 5 P¹¹ is ^DDab, ^DDap, ^DOrn, ^DLys, ^DArg, or ^DDab(iPr);
 P¹² is Lys, Ile, Ser, Tyr, Trp, Asn, Dab, Orn, or Cit;
 P¹³ is Cys, Pen, Dab, or Abu(4N₃);
 P¹⁴ is Dab, Dab(iPr), Lys, Gln, Ser, or Tyr;
 P¹⁵ is Arg, Thr, Leu, Ser, Dab, Lys, Orn, or Orn(iPr); and
 10 P¹⁶ is Nle, Cha, or Tyr;
 or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof,
 wherein Cys or Pen at P⁶, if present, and Cys or Pen at P¹³, if present, optionally form a
 disulfide bridge between P⁶ and P¹³, or wherein
 Asp at P⁶, if present, and Dab at P¹³, if present, optionally form a lactam bridge
 15 between P⁶ and P¹³, or wherein
 Pra at P⁶, if present, and Abu(4N₃) at P¹³, if present, optionally form a 1,2,3-triazole
 bridge between P⁶ and P¹³;
 with the proviso that at least three amino acid residues among the four amino acid
 residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from
 20 Dab, Lys, Arg, or Dab(iPr) at P⁹, Lys, Dab, or Orn at P¹², Dab, Dab(iPr), or Lys at P¹⁴ and
 Arg, Dab, Lys, Orn or Orn(iPr) at P¹⁵.

8. The compound according to any one of claims 1 to 7, wherein
 P¹ is Val, NMeVal, Gua-Val, TMG-Val, or Abu;
 25 P² is Pro, Pro(4R)OMe, Pro(3,4dehydro), Pic, Pro((4R)NH₂), Ndab, *Nallo*Thr, or Hyp;
 P³ is Ile;
 P⁴ is Ile, Thr, Phe, Dab, Arg, Val(3OH), or Tyr;
 P⁵ is Tyr;
 P⁶ is Cys, Pen, or Asp;
 30 P⁷ is Asn, Leu, Ile, Ser, Dap, or His;

- P⁸ is Arg;
 P⁹ is Arg, Lys, Dab, or Dab(iPr);
 P¹⁰ is Ser or Thr;
 P¹¹ is ^DDab, ^DDab(iPr), or ^DArg;
 5 P¹² is Lys, Ile, Ser, Dab, Orn, or *Cit*;
 P¹³ is Cys, Pen, or Dab;
 P¹⁴ is Dab, Dab(iPr), Lys, Gln, Ser, or Tyr;
 P¹⁵ is Arg, Dab, Orn, Orn(iPr), Ser, or Thr;
 P¹⁶ is Nle, Cha, or Tyr;
 10 or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof,
 wherein Cys or Pen at P⁶, if present, and Cys or Pen at P¹³, if present, optionally form a
 disulfide bridge between P⁶ and P¹³, or wherein
 Asp at P⁶, if present, and Dab at P¹³, if present, optionally form a lactam bridge
 between P⁶ and P¹³;
 15 with the proviso that at least three amino acid residues among the four amino acid
 residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from
 Dab, Lys, Arg, or Dab(iPr) at P⁹, Lys, Orn, or Dab at P¹², Lys, Dab or Dab(iPr) at P¹⁴ and
 Arg, Dab, Orn, or Orn(iPr) at P¹⁵.
- 20 9. The compound according to any one of claims 1 to 7, wherein
 P¹ is 2OHVal, Gua-Val, or TMG-Val;
 P² is Pro, Pro((4R)NH₂), or Hyp;
 P³ is Ile;
 P⁴ is Ile, Thr, Dab, or Orn;
 25 P⁵ is Tyr;
 P⁶ is Cys, Pen, Asp or Pra;
 P⁷ is Ile, Asn, or Thr;
 P⁸ is Arg;
 P⁹ is Lys, Arg, Dab, or Dab(iPr);
 30 P¹⁰ is Ser, or Thr;

P¹¹ is ^DDab, ^DDab(iPr), or ^DDap;

P¹² is Lys, Ile, Asn, Ser, Tyr, Orn, or Cit;

P¹³ is Cys, Dab, or Abu(4N₃);

P¹⁴ is Dab, Dab(iPr), Lys, or Ser;

5 P¹⁵ is Arg, Dab, Orn; Orn(iPr), Ser, or Thr;

P¹⁶ is Nle, or Tyr;

or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof,

wherein Cys or Pen at P⁶, if present, and Cys at P¹³, if present, optionally form a disulfide bridge between P⁶ and P¹³, or wherein

10 Asp at P⁶, if present, and Dab at P¹³, if present, optionally form a lactam bridge between P⁶ and P¹³; or wherein

Pra at P⁶, if present, and Abu(4N₃) at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³;

with the proviso that at least three amino acid residues among the four amino acid

15 residues at positions P⁹, P¹², P¹⁴ and P¹⁵ are basic amino acid residues selected from Dab, Lys, Arg, or Dab(iPr) at P⁹, Lys, or Orn at P¹², Lys, Dab or Dab(iPr) at P¹⁴ and Arg, Dab, Orn, or Orn(iPr) at P¹⁵.

10. A compound according to any one of claims 1 to 7, wherein the compound is
20 selected from the group consisting of

Val-Pro-Ile-Ile-Tyr-Cys-Asn-Arg-Arg-Thr-^DDab-Lys-Cys-Dab-Arg-Nle;

Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Arg-Thr-^DDab-Lys-Cys-Dab-Arg-Nle;

Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Nle;

Val-Ndab-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Nle;

25 Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Nle;

Val-Pro-Ile-Ile-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Cha;

Val-Pro-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;

Val-Pro-Ile-Ile-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Pen-Dab-Arg-Tyr;

Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;

30 Val-Hyp-Ile-Ile-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;

- Val-Pro-Ile-Thr-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Pro-Ile-Phe-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
2OHVal-Pro-Ile-Ile-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
5 Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDap-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DOrn-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DLys-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DArg-Lys-Cys-Dab-Arg-Tyr;
10 Val-Hyp-Ile-Dab-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Thr-Tyr;
Val-Hyp-Ile-Arg-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Thr-Tyr;
Val-Hyp-Ile-Tyr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Leu-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Asn-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
15 Val-Hyp-Ile-Dab-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Lys-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Trp-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Ala-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Leu-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
20 Val-Hyp-Ile-Thr-Tyr-Pen-Ile-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Ser-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Thr-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Lys-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Lys-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
25 Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Arg-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ile-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ser-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Tyr-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Trp-Cys-Dab-Arg-Tyr;
30 Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Asn-Cys-Dab-Arg-Tyr;

- Va-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Dab-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Leu-Tyr
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Ser-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Dab-Tyr;
5 Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Lys-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Orn-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Cit-Cys-Dab-Arg-Tyr;
NMeVal-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Dap-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
10 Val-Hyp-Ile-Dap-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Arg-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Tyr-Arg-Tyr;
Gua-Val-Pro-Ile-Ile-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Gua-Val-Pro-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
15 Gua-Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Gua-Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Gua-Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Gua-Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Gua-Val-Hyp-Ile-Tyr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Gln-Arg-Tyr;
20 Gua-Val-Hyp-Ile-Thr-Tyr-Pen-Glu-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Gua-Val-Hyp-Ile-Thr-Tyr-Pen-His-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Gua-Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Dab-Cys-Dab-Arg-Tyr;
Gua-Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Arg-Tyr;
Gua-Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Dab-Tyr;
25 Gua-Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Orn-Tyr;
Gua-Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Tyr-Arg-Tyr;
Gua-Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Tyr-Arg-Tyr;
Gua-Val-Hyp-Ile-alloThr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Tyr-Arg-Tyr;
TMG-Val-Pro-Ile-Ile-Tyr-Cys-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
30 TMG-Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;

- Val-Hyp-Ile-Ile-Tyr-Pra-Asn-Arg-Dab-Thr-^DDab-Lys-Abu(4N₃)-Dab-Arg-Tyr;
Val-Hyp-Ile-Ile-Tyr-Asp-Asn-Arg-Dab-Thr-^DDab-Lys-Dab-Dab-Arg-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Cit-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Dab-Tyr;
5 Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Dab-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Dab-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Orn-Cys-Dab-Arg-Tyr;
Abu-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
10 Val-Pro-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Dab-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Dab-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Lys-Thr-^DDab-Lys-Cys-Lys-Arg-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ile-Cys-Dab-Dab-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Ile-Cys-Dab-Dab-Tyr;
15 Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Orn-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Orn-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ile-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Ile-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Orn-Tyr;
Val-Hyp-Ile-Dab-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Orn-Tyr;
20 Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ile-Cys-Dab-Arg-Tyr;
Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Cit-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Ile-Arg-Dab-Thr-^DDab-Lys-Cys-Ser-Orn-Tyr;
Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Ser-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Orn-Tyr;
25 tBuGly-Hyp-Ile-Thr-Tyr-Pen-Ile-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Orn-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Ile-Cys-Dab-Orn-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ile-Cys-Dab-Orn-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Cit-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Ile-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Ser-Tyr;
30 Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Ser-Tyr;

- Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ser-Cys-Dab-Arg-Tyr;
Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Cit-Cys-Dab-Ser-Tyr;
Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Ser-Ser-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Ile-Arg-Dab-Thr-^DDab-Lys-Cys-Ser-Arg-Tyr;
5 Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Ser-Tyr;
Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Cit-Cys-Dab-Ser-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Ser-Arg-Tyr;
Val-Hyp-Ile-Dab-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Cit-Cys-Dab-Ser-Tyr;
Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Thr-Tyr;
10 Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Ser-Arg-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Thr-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Lys-Cys-Dab-Thr-Tyr;
Val-Hyp-Ile-Dab-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Cit-Cys-Dab-Thr-Tyr;
tBuGly-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
15 Val-Pro((4R)NH₂)-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ile-Cys-Dab-Thr-Tyr;
Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Cit-Cys-Dab-Thr-Tyr;
Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Ile-Cys-Dab-Thr-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Dab-Ser-^DDab-Ile-Cys-Dab-Arg-Tyr;
Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Ser-Thr-Tyr;
20 Val-Pro((4R)NH₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Thr-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Orn-Thr-^DDab-Ile-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Orn-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Thr-Tyr;
Val-Hyp-Ile-Thr-Tyr-Pen-Ile-Arg-Dab-Thr-^DDab-Orn-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Ile-Tyr-Pen-Asn-Arg-Cit-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
25 Val-Hyp-Ile-Lys(Me)-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Hyp-Ile-Val(3OH)-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Pro(4,4F₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Pro(3,4dehydro)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
Val-Pro(4,4F₂)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;
30 Val-Pro((4R)OPh)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr

Val-Pro((4R)F)-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;

Val-Pic-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;

Val-NalloThr-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Arg-Tyr;

Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab(iPr)-Thr-^DDab-Lys-Cys-Dab-Orn(iPr)-Tyr;

5 Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab(iPr)-Thr-^DDab-Lys-Cys-Dab(iPr)-Arg-Tyr;

Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Orn(iPr)-Tyr;

Hyp-Ile-Thr-Tyr-Pen-Ile-Arg-Dab-Thr-^DDab-Lys-Cys-Dab-Orn(iPr)-Tyr;

Hyp-Ile-Thr-Tyr-Pen-Asn-Arg-Dab-Thr-^DDab(iPr)-Lys-Cys-Dab-Arg-Tyr; (Ex138)

or a tautomer, a rotamer, a salt, a hydrate or a solvate thereof,

10 wherein Cys or Pen at P⁶, if present, and Cys or Pen at P¹³, if present, optionally form a disulfide bridge between P⁶ and P¹³, or wherein

Asp at P⁶, if present, and Dab at P¹³, if present, optionally form a lactam bridge between P⁶ and P¹³, or wherein

15 Pra at P⁶, if present, and Abu(4N₃) at P¹³, if present, optionally form a 1,2,3-triazole bridge between P⁶ and P¹³.

11. An enantiomer of a compound of formula (I) as defined in claim 1.

12. A pharmaceutical composition containing a compound or a mixture of
20 compounds according to any one of claims 1 to 11 and at least one pharmaceutically inert carrier.

13. A pharmaceutical composition according to claim 12 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, rectal, pulmonary or inhalation
25 administration, especially in the form of a tablet, a dragee, a capsule, a solution, a liquid, a gel, a plaster, a cream, an ointment, a syrup, a slurry, a suspension, a spray, a nebulizer, an aerosol, or a suppository.

14. A compound of formula (I) according to any one of claims 1 to 11, or a
30 pharmaceutically acceptable salt thereof, for use as a medicament.

15. A compound according to any one of the claims 1 to 11 for use as a pharmaceutically active substance having antibiotic activity.

16. Use of a compound according to any one of claims 1 to 11 for the manufacture
5 of a medicament to treat or prevent infections or diseases related to such infections; particularly infections related to respiratory diseases or skin or soft tissue diseases or gastrointestinal diseases or eye diseases or ear diseases or CNS diseases or bone diseases or cardiovascular diseases or genitourinary diseases, or nosocomial infections, or catheter-related and non-catheter-related infections, or urinary tract infections, or
10 bloodstream infections; or infection-induced sepsis.

17. Use of a compound according to any one of claims 1 to 11 as a disinfectant or preservative for foodstuffs, cosmetics, medicaments, and/or other nutrient-containing materials.

15

18. Use of a compound according to any one of claims 1 to 11 as a pharmaceutically active substance having antibiotic activity.

19. Use of a compound according to any one of claims 1 to 11 or a composition according to claim 12 or 13 for the treatment or prevention of infections or diseases
20 related to such infections; particularly infections related to respiratory diseases or skin or soft tissue diseases or gastrointestinal diseases or eye diseases or ear diseases or CNS diseases or bone diseases or cardiovascular diseases or genitourinary diseases, or nosocomial infections, or catheter-related and non-catheter-related infections, or urinary tract infections, or bloodstream infections; or infection-induced sepsis.

25

20. Use of a compound according to any one of claims 1 to 11 or a composition according to claim 12 or 13 as a disinfectant or preservative for foodstuffs, cosmetics, medicaments and/or other nutrient-containing materials.

~~21. — A method of treating an infection, especially infections such as nosocomial infections, catheter-related and non-catheter-related infections, urinary tract infections, bloodstream infections, or a disease or disorder associated with an infection, especially diseases or disorders such as ventilator-associated pneumonia (VAP), ventilator-associated bacterial pneumonia (VABP), hospital-acquired pneumonia (HAP), hospital-acquired bacterial pneumonia (HABP), healthcare-associated pneumonia (HCAP), cystic fibrosis, emphysema, asthma, pneumonia, epidemic diarrhea, necrotizing enterocolitis, typhlitis, gastroenteritis, pancreatitis, keratitis, endophthalmitis, otitis, brain abscess, meningitis, encephalitis, osteochondritis, pericarditis, epididymitis, prostatitis, urethritis, sepsis; surgical wounds, traumatic wounds, burns, comprising the step:~~

~~administering to a subject in need thereof a pharmaceutically acceptable amount of a compound or a mixture of compounds according to any one of claims 1 to 11 or a therapeutically active amount of a pharmaceutical composition according to claim 12 or 13.~~

21. Use of a pharmaceutically acceptable amount of a compound or a mixture of compounds according to any one of claims 1 to 11 or a therapeutically active amount of a pharmaceutical composition according to claim 12 or 13 in the manufacture of a medicament for treating an infection, especially infections such as nosocomial infections, catheter-related and non-catheter-related infections, urinary tract infections, bloodstream infections, or a disease or disorder associated with an infection, especially diseases or disorders such as ventilator-associated pneumonia (VAP), ventilator-associated bacterial pneumonia (VABP), hospital-acquired pneumonia (HAP), hospital-acquired bacterial pneumonia (HABP), healthcare-associated pneumonia (HCAP), cystic fibrosis, emphysema, asthma, pneumonia, epidemic diarrhea, necrotizing enterocolitis, typhlitis, gastroenteritis, pancreatitis, keratitis, endophthalmitis, otitis, brain abscess, meningitis, encephalitis, osteochondritis, pericarditis, epididymitis, prostatitis, urethritis, sepsis; surgical wounds, traumatic wounds, and burns.

22. A process for the preparation of a compound according to any one of claims 1 to 11 which comprises the following steps:

- (a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position P¹⁶; any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (b) removing the N-protecting group from the product thus obtained;

- (c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position P¹⁵; any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;
- (d) effecting steps substantially corresponding to steps (b) and (c) using appropriately N-protected derivatives of amino acids which in the desired end-product are in positions P¹⁴ to P⁶, any functional group(s) which may be present in said N-protected amino acid derivatives being likewise appropriately protected;
- (e) optionally selectively deprotecting one or several protected functional group(s) present in the molecule and chemically transforming the reactive group(s) thus liberated;
- (f) effecting steps substantially corresponding to steps (b) and (c) using appropriately N-protected derivatives of amino acids which in the desired end-product are in positions P⁵ to P², any functional group(s) which may be present in said N-protected amino acid derivatives being likewise appropriately protected; and, optionally, following each coupling, selectively deprotecting one or several protected functional group(s) present in the molecule and chemically transforming the reactive group(s) thus liberated;
- (g) further effecting steps substantially corresponding to steps (b) and (c) using an appropriately N-protected derivative of an amino acid, or optionally, an appropriately protected derivative of a hydroxy acid, which in the desired end-product is in position P¹, any functional group(s) which may be present in said N-protected amino acid derivative, or hydroxy acid derivative, being likewise appropriately protected; and, optionally, following the coupling, selectively deprotecting one or several protected functional group(s) present in the molecule and chemically transforming the reactive group(s) thus liberated;
- (h) optionally selectively deprotecting one or several protected functional group(s) present in the molecule and chemically transforming the reactive group(s) thus liberated;
- (i) optionally, removing the N-protecting group at position P¹;
- (j) detaching the product thus obtained from the solid support;
- (k) optionally selectively deprotecting one or several protected functional group(s) present in the molecule and chemically transforming the reactive group(s) thus liberated;
- (l) removing any protecting groups present on functional groups of any members of the chain of residues and, optionally, any protecting group(s) which may in addition be present in the molecule;

- (m) optionally implementing additional chemical transformations of one or more reactive group(s) present in the molecule;
- (n) if required, removing any protecting groups present on functional groups of any members of the chain of residues and, optionally, any protecting group(s) which may in addition be present in the molecule; and
- (o) optionally converting the product thus obtained into a pharmaceutically acceptable salt; or optionally converting a pharmaceutically acceptable or unacceptable salt thus obtained into the corresponding free compound of formula (I); or optionally converting a pharmaceutically acceptable or unacceptable salt thus obtained into a different, pharmaceutically acceptable salt.